High materiality7/10
StoneX Reiterates Buy Rating on Kamada Ltd. (KMDA) on Increased Demand for Anti-Rabies Treatment
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS target update: Buy rating; Target $15; Current price $8.84.
- UBS target update: Buy rating; Target $15; Price $8.84.
Key facts
- 01
Target: $15
- 02
Posted price: $8.84
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.